 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Get Free Report) have been assigned a consensus rating of Moderate Buy from the ten analysts that are currently covering the...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Brokerages

Wedbush reissued their outperform rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) in a research report report published on Wednesday morning, RTT News reports...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Outperform Rating at Wedbush

Cantor Fitzgerald restated their overweight rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) in a research report report published on Tuesday, Benzinga reports. The...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by Cantor Fitzgerald

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Get Free Report) shot up 2.3% during trading on Wednesday after Barclays raised their price target on the stock from $41.00 to $59.00...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 2.3% Following Analyst Upgrade

HC Wainwright reiterated their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC Wainwright

Scinai s NanoAbs downregulated key molecular markers overexpressed in plaque psoriasis Stratum corneum regained normal appearance in laboratory 3D skin model Results from ex-vivo study...

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

MoonLake Immunotherapeutics (NASDAQ:MLTX  Get Free Report)s stock had its buy rating reissued by analysts at Needham  Company LLC in a report issued on Tuesday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from Needham & Company LLC

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 ZUG, Switzerland, September 6, 2023 MoonLake Immunotherapeutics AG ( MoonLake ; Nasdaq: MLTX), a clinical-stage...

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

Cabaletta Bio, Reata Pharmaceuticals, and MoonLake Immunotherapeutics provided the best 1-year total returns as of mid-August...

Top Stocks for September 2023

Needhaminitiated coverage onMoonLake Immunotherapeutics(NASDAQ: MLTX) with a Buy rating andread more...

Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Watchers	442
52-Wk Low	$6.93
52-Wk High	$63.40

Market Cap	$2.97B
Volume (M)	45,394.00
52-Wk High	$63.40
52-Wk Low	$6.93

MLTX MoonLake Immunotherapeutics - Ordinary Shares - Class A

About

Feed

News

Sentiment

Fundamentals